"The Lifespan Cancer Institute at Rhode Island Hospital provides the most current cancer diagnosis and treatment options for nearly 40 types of cancer. Cancer treatments include the latest chemotherapy, biologic agents, radiation oncology, surgery, and image-guided procedures—many of which are not available elsewhere in New England. Our world-renowned physicians and specialists form multidisciplinary teams whose collective level of knowledge and experience is unparalleled in the region. We have created a strategic alliance with the Dana-Farber Cancer Institute to advance cancer treatment, enable collabortation on complex cancer cases, coordinate the care of bone marrow transplant patients and expand access to clinical trials."

During the past decade, Lifespan Cancer Institute conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 2 clinical trials were completed, i.e. on average, 6.5% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 2 clinical trials were completed. i.e. 9.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lifespan Cancer Institute" #1 sponsor was "Brown University" with 8 trials, followed by "Dana-Farber Cancer Institute" with 6 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored and "Bristol-Myers Squibb" with 3 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lifespan Cancer Institute" #1 collaborator was "AstraZeneca" with 3 trials as a collaborator, "Rhode Island Hospital" with 3 trials as a collaborator, "Actuate Therapeutics Inc." with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator and "Susan G. Komen Breast Cancer Foundation" with 2 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Lifespan Cancer Institute" are "Breast Cancer" (3 trials), "Angiosarcoma" (2 trials), "Bone Sarcoma" (2 trials), "High Grade Sarcoma" (2 trials) and "Leiomyosarcoma" (2 trials). Many other conditions were trialed in "Lifespan Cancer Institute" in a lesser frequency.

Most popular intervention types in "Lifespan Cancer Institute" are "Drug" (26 trials), "Behavioral" (2 trials), "Device" (2 trials), "Genetic" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (3 trials), "9-ING-41" (2 trials), "Carboplatin" (2 trials), "Docetaxel" (2 trials) and "Gemcitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Lifespan Cancer Institute" are 24 trials for "All" genders, 4 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Lifespan Cancer Institute". 2 are not yet recruiting, 12 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Lifespan Cancer Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Lifespan Cancer Institute, 13 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".